A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Phase 2

Completed

• Conditions: Postherpetic Neuralgia

• Registration Number: NCT00168441
• Lead Sponsor: Allergan

Brief Summary

4-month study including a 30-day baseline phase

Detailed Description

Not available

Study Timeline

• Study Start: 2004-06
• Primary Completion: 2005-06
• Study Completion: 2005-06
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-15
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-27
• Last Update Posted: 2011-05-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

• Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion Criteria

• Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Pain score

Secondary Outcome Measures

Name	Time	Method
Various Quality of Life questionnaires
Reduction in area of pain/allodynia